CLVR · Clever Leaves Holdings Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $3.82M | $4.98M | $3.98M | - | $3.31M | $4.66M | $5.22M | - | $3.92M |
| Cost of Revenue | - | $1.88M | $2.25M | $1.74M | - | $3.02M | $3.35M | $3.19M | - | $1.84M |
| Gross Profit | - | $1.94M | $2.73M | $2.23M | - | $280.0K | $1.30M | $2.04M | - | $2.54M |
| R&D | - | $292.0K | $403.0K | $212.0K | - | $343.0K | $359.0K | $412.0K | - | - |
| SG&A | - | $4.16M | $4.80M | $5.37M | - | $6.09M | $8.01M | $8.26M | - | $11.07M |
| Total Operating Expenses | - | $5.32M | $5.90M | $6.36M | - | $26.47M | $9.50M | $13.93M | - | $12.22M |
| D&A | - | $290.0K | $224.0K | $236.0K | - | $508.0K | $537.0K | $517.0K | - | $534.0K |
| Operating Income | - | ($3.38M) | ($3.17M) | ($4.13M) | - | ($26.19M) | ($8.20M) | ($11.89M) | - | ($9.68M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($5.14M) | ($3.60M) | ($4.08M) | - | ($20.16M) | ($1.05M) | ($16.14M) | - | ($5.09M) |
| EPS - Basic | - | ($3.25) | ($2.40) | ($2.70) | - | ($14.40) | ($0.90) | ($17.40) | - | ($14.40) |
| EPS - Diluted | - | ($3.25) | ($2.40) | ($2.70) | - | ($14.40) | ($0.90) | ($17.40) | - | $1.20 |
Balance Sheet
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.83M | $6.47M | $5.08M | $6.36M | $12.45M | $17.18M | $19.02M | $44.31M | $37.23M | $45.76M |
| Accounts Receivable | $907.0K | $1.75M | $2.59M | $2.65M | $2.25M | $2.59M | $3.39M | $2.58M | $2.22M | $2.16M |
| Inventory | $4.48M | $7.71M | $7.47M | $8.02M | $8.40M | $16.65M | $16.74M | $16.23M | $15.41M | $14.06M |
| Accounts Payable | $2.06M | $2.09M | $2.30M | $1.78M | $2.30M | $2.34M | $3.23M | $4.37M | $3.98M | $2.87M |
| Current Assets | $13.94M | $17.93M | $18.41M | $21.13M | $26.25M | $40.55M | $44.27M | $69.16M | $60.39M | $68.08M |
| Total Assets | $31.24M | $37.78M | $42.83M | $46.24M | $52.10M | $81.42M | $105.46M | $127.22M | $116.16M | $141.14M |
| Current Liabilities | $5.81M | $6.85M | $7.56M | $7.80M | $9.43M | $8.22M | $8.64M | $27.49M | $27.25M | $32.65M |
| Long-term Debt | $1.22M | $1.34M | $1.38M | $1.48M | $1.06M | $1.38M | $1.61M | $6.15M | $7.59M | $5.86M |
| Total Liabilities | $7.03M | $8.09M | $8.88M | $9.47M | $11.69M | $11.91M | $20.87M | $44.77M | $43.39M | $53.47M |
| Stockholders' Equity | $24.22M | $29.69M | $33.95M | $36.77M | $40.41M | $69.50M | $84.59M | $82.45M | $72.77M | $87.67M |
| Retained Earnings | ($198.80M) | ($193.72M) | ($188.58M) | ($184.99M) | ($180.91M) | ($152.09M) | ($131.93M) | ($130.88M) | ($114.74M) | ($90.74M) |
Cash Flow
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($6.08M) | - | - | - | ($10.37M) | - | - |
| Investing Cash Flow | - | - | - | ($35.0K) | - | - | - | ($1.22M) | - | - |
| Financing Cash Flow | - | - | - | ($107.0K) | - | - | - | $18.69M | - | - |
| CapEx | - | - | - | $35.0K | - | - | - | $1.22M | - | - |
| Free Cash Flow | - | - | - | ($6.11M) | - | - | - | ($11.59M) | - | - |
Ratios
| Metric | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 50.8% | 54.7% | 56.2% | - | 8.5% | 28.0% | 39.0% | - | 64.7% |
| Operating margin | - | -88.4% | -63.7% | -103.8% | - | -792.5% | -176.0% | -227.7% | - | -247.2% |
| EBITDA margin | - | -80.8% | -59.2% | -97.9% | - | -777.1% | -164.5% | -217.8% | - | -233.6% |
| Net margin | - | -134.5% | -72.2% | -102.6% | - | -610.1% | -22.5% | -309.0% | - | -130.0% |
| Free cash flow margin | - | - | - | -153.6% | - | - | - | -221.8% | - | - |
| FCF / Net income | - | - | - | 1.50 | - | - | - | 0.72 | - | - |
| R&D / Revenue | - | 7.6% | 8.1% | 5.3% | - | 10.4% | 7.7% | 7.9% | - | - |
| SG&A / Revenue | - | 108.8% | 96.5% | 134.9% | - | 184.2% | 172.1% | 158.1% | - | 282.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -13.6% | -8.4% | -8.8% | - | -24.8% | -1.0% | -12.7% | - | -3.6% |
| Return on equity | - | -17.3% | -10.6% | -11.1% | - | -29.0% | -1.2% | -19.6% | - | -5.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.40 | 2.62 | 2.43 | 2.71 | 2.78 | 4.93 | 5.12 | 2.52 | 2.22 | 2.09 |
| Quick ratio | 1.63 | 1.49 | 1.45 | 1.68 | 1.89 | 2.91 | 3.18 | 1.93 | 1.65 | 1.65 |
| Cash ratio | 1.18 | 0.95 | 0.67 | 0.82 | 1.32 | 2.09 | 2.20 | 1.61 | 1.37 | 1.40 |
| Leverage | ||||||||||
| Debt / Equity | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 | 0.02 | 0.02 | 0.07 | 0.10 | 0.07 |
| Debt / Assets | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.05 | 0.07 | 0.04 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.29 | 1.27 | 1.26 | 1.26 | 1.29 | 1.17 | 1.25 | 1.54 | 1.60 | 1.61 |
| Liabilities / Assets | 0.22 | 0.21 | 0.21 | 0.20 | 0.22 | 0.15 | 0.20 | 0.35 | 0.37 | 0.38 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.10 | 0.12 | 0.09 | - | 0.04 | 0.04 | 0.04 | - | 0.03 |
| Inventory turnover | - | 0.24 | 0.30 | 0.22 | - | 0.18 | 0.20 | 0.20 | - | 0.13 |
| Days sales outstanding | - | 167d | 190d | 243d | - | 286d | 266d | 180d | - | 201d |
| Days inventory outstanding | - | 1498d | 1209d | 1677d | - | 2009d | 1822d | 1859d | - | 2783d |
| Days payable outstanding | - | 406d | 372d | 372d | - | 282d | 351d | 501d | - | 568d |
| Cash conversion cycle | - | 1259d | 1027d | 1549d | - | 2013d | 1737d | 1539d | - | 2417d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | 194.0x |
| P / B | - | 0.2x | 8.0x | 13.7x | - | 11.0x | 13.7x | 25.3x | - | 68.4x |
| P / S | - | 1.4x | 54.8x | 126.4x | - | 230.7x | 248.7x | 399.8x | - | 1530.8x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 15.6% | 7.0% | -23.9% | - | -15.6% | 26.8% | 79.3% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | 593.6% | 109.0% | 9.6% | - | -89.0% | -44.1% | -5.7% | - | - |
| Operating income growth (YoY) | - | 87.1% | 61.3% | 65.3% | - | -170.5% | 14.6% | -29.6% | - | - |
| Net income growth (YoY) | - | 74.5% | -243.7% | 74.7% | - | -295.8% | 86.9% | -73.9% | - | - |
| EPS growth (YoY) | - | 77.4% | -166.7% | 84.5% | - | - | -157.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 47.2% | - | - | - | -30.5% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -40.1% | -57.3% | -59.9% | -55.4% | -44.5% | -20.7% | 7.3% | -2.4% | -36.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Business segments
$17.42M totalNon Cannabinoid$10.86M · 62.3%
Cannabinoid$6.56M · 37.7%
Geographic
$17.42M totalUS$10.86M · 62.3%
BR$3.10M · 17.8%
AU$1.68M · 9.7%
Other Countries Not Separately Disclosed$941.0K · 5.4%
IL$600.0K · 3.4%
DE$235.0K · 1.3%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Clever Leaves Holdings Inc. against the 5 most active filers in the same SIC group.